AASLD-EASL HBV Endpoints 2022
3-4 June, 2022
Washington, US
ENYO Pharma was attending AASLD-EASL HBV Endpoints 2022 to share news on therapeutic endpoints, trial designs and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. It was a great opportunity to meet academic, regulatory, pharmaceutical communities and patients in liver disease area.
https://easl.eu/event/aasld-easl-endpoints-2022/